Bioxytran publishes preprint on galectin-3's role in ICI resistance and potential enhancement

BIOXYTRAN, INC

Preprint reviews theories that galectin-3 contributes to ICI resistance; galectin-3 antagonists may reverse effect.
90% of high galectin-3 NSCLC patients failed to respond to ICI after 3 treatments.
Surface Plasmon Resonance and cryo-EM confirm galectin-3 blocks ICI binding to PD-1 receptor.
Company also published cancer presentation on galectin antagonists in cancer.
CEO states findings herald significant shift in cancer treatment paradigms.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.